The DOI matches its Crossref record; 134 of the 134 references it cites were found in a registry or an index.
The First Decade of Biologic TNF Antagonists in Clinical Practice: Lessons Learned, Unresolved Issues and Future Directions
Abstract
Results from clinical trials of biologic anti-TNF drugs performed in the late 1990s confirmed the biological relevance of TNF function in the pathogenesis of chronic noninfectious inflammation of joints, skin and gut, which collectively affects 2-3% of the population. Up to April 2009, more than two million patients worldwide have received the first marketed drugs, namely the monoclonal anti-TNF antibodies infliximab and adalimumab and the soluble TNF receptor etanercept. All three are equally effective in rheumatoid arthritis, ankylosing spondylitis, psoriasis and psoriatic arthritis, but, for not clearly defined reasons, only the monoclonal antibodies are effective in inflammatory bowel disease. About 60% of patients who do not benefit from standard nonbiologic treatments for these diseases respond to TNF antagonists. Less than half of responding patients achieve complete remission of disease. Importantly, some of those patients with rheumatoid arthritis in whom long-term anti-TNF therapy induced disease remission remain disease-free after discontinuation of any kind of treatment. There are not yet reliable predictors of which patients will or will not respond on anti-TNF therapy, whereas subsequent loss of an initial clinical response occurs frequently. The spectrum of efficacy anti-TNF therapies widens to include diseases such as systemic vasculitis and sight-threatening uveitis. While paradoxical new adverse effects are recognized, i.e. exacerbation or development of new onset psoriasis, reactivation of latent tuberculosis remains the most important safety issue of anti-TNF therapies. Clinical practice guidelines and consensus statements on the criteria of introduction, duration of treatment and cessation of TNF antagonists, including safety issues, are under constant revision as data from longer periods of patient exposure accumulate. It is hoped that more efficacious drugs that will ideally target the deleterious proinflammatory properties of TNF without compromising its protective role in host defense and (auto)immunity will be available in the near future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
Rutgeerts, P., Sandborn, W. J., Feagan, B. G., Reinisch, W., Olson, A., Johanns, J., Travers, S., Rachmilewitz, D., Hanauer, S. B., Lichtenstein, G. R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050516 · Cited by 3,902
Targan, S. R., Hanauer, S. B., van Deventer, S. J. H., Mayer, L., Present, D. H., Braakman, T., DeWoody, K. L., Schaible, T. F., & Rutgeerts, P. J. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710093371502 · Cited by 3,135
Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis
Lipsky, P. E., van der Heijde, D. M. F. M., St. Clair, E. W., Furst, D. E., Breedveld, F. C., Kalden, J. R., Smolen, J. S., Weisman, M., Emery, P., Feldmann, M., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011303432202 · Cited by 2,996
Infliximab for the Treatment of Fistulas in Patients with Crohn's Disease
Present, D. H., Rutgeerts, P., Targan, S., Hanauer, S. B., Mayer, L., van Hogezand, R. A., Podolsky, D. K., Sands, B. E., Braakman, T., DeWoody, K. L., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199905063401804 · Cited by 2,752
Weinblatt, M. E., Kremer, J. M., Bankhurst, A. D., Bulpitt, K. J., Fleischmann, R. M., Fox, R. I., Jackson, C. G., Lange, M., & Burge, D. J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901283400401 · Cited by 2,085
Breedveld, F. C., Weisman, M. H., Kavanaugh, A. F., Cohen, S. B., Pavelka, K., Vollenhoven, R. V., Sharp, J., Perez, J. L., & Spencer‐Green, G. T. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21519 · Cited by 1,785
Weinblatt, M. E., Keystone, E. C., Furst, D. E., Moreland, L. W., Weisman, M. H., Birbara, C. A., Teoh, L. A., Fischkoff, S. A., & Chartash, E. K. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10697 · Cited by 1,757
Klareskog, L., van der Heijde, D., de Jager, J. P., Gough, A., Kalden, J., Malaise, M., Mola, E. M., Pavelka, K., Sany, J., Settas, L., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15640-7 · Cited by 1,751
Chung, E. S., Packer, M., Lo, K. H., Fasanmade, A. A., & Willerson, J. T. (2003) · Circulation · doi:10.1161/01.cir.0000077913.60364.d2 · Cited by 1,644
Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
Tracey, D., Klareskog, L., Sasso, E. H., Salfeld, J. G., & Tak, P. P. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.10.001 · Cited by 1,628
Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial
Mease, P. J., Goffe, B. S., Metz, J., VanderStoep, A., Finck, B., & Burge, D. J. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02530-7 · Cited by 1,446
Etanercept Therapy in Rheumatoid Arthritis: A Randomized, Controlled Trial
Moreland, L. W., Schiff, M. H., Baumgartner, S. W., Tindall, E. A., Fleischmann, R. M., Bulpitt, K. J., Weaver, A. L., Keystone, E. C., Furst, D. E., Mease, P. J., et al. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00004 · Cited by 1,379
Braun, J., Brandt, J., Listing, J., Zink, A., Alten, R., Golder, W., Gromnica-lhle, E., Kellner, H., Krause, A., Schneider, M., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08215-6 · Cited by 1,261
Etanercept in Children with Polyarticular Juvenile Rheumatoid Arthritis
Lovell, D. J., Giannini, E. H., Reiff, A., Cawkwell, G. D., Silverman, E. D., Nocton, J. J., Stein, L. D., Gedalia, A., Ilowite, N. T., Wallace, C. A., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003163421103 · Cited by 1,246
Mann, D. L., McMurray, J. J. V., Packer, M., Swedberg, K., Borer, J. S., Colucci, W. S., Djian, J., Drexler, H., Feldman, A., Kober, L., et al. (2004) · Circulation · doi:10.1161/01.cir.0000124490.27666.b2 · Cited by 1,240
Guidelines of care for the management of psoriasis and psoriatic arthritis
Menter, A., Gottlieb, A., Feldman, S. R., Van Voorhees, A. S., Leonardi, C. L., Gordon, K. B., Lebwohl, M., Koo, J. Y. M., Elmets, C. A., Korman, N. J., et al. (2008) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2008.02.039 · Cited by 1,222
Keystone, E. C., Kavanaugh, A. F., Sharp, J. T., Tannenbaum, H., Hua, Y., Teoh, L. S., Fischkoff, S. A., & Chartash, E. K. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20217 · Cited by 1,172
St. Clair, E. W., van der Heijde, D. M. F. M., Smolen, J. S., Maini, R. N., Bathon, J. M., Emery, P., Keystone, E., Schiff, M., Kalden, J. R., Wang, B., et al. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20568 · Cited by 1,143
Certolizumab Pegol for the Treatment of Crohn's Disease
Sandborn, W. J., Feagan, B. G., Stoinov, S., Honiball, P. J., Rutgeerts, P., Mason, D., Bloomfield, R., & Schreiber, S. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067594 · Cited by 1,143
Järnerot, G., Hertervig, E., Friis-Liby, I., Blomquist, L., Karlén, P., Grännö, C., Vilien, M., Ström, M., Danielsson, Å., Verbaan, H., et al. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.03.003 · Cited by 1,089
Reich, K., Nestle, F. O., Papp, K., Ortonne, J.-P., Evans, R., Guzzo, C., Li, S., Dooley, L. T., & Griffiths, C. E. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67566-6 · Cited by 1,045
Maintenance Therapy with Certolizumab Pegol for Crohn's Disease
Schreiber, S., Khaliq-Kareemi, M., Lawrance, I. C., Thomsen, O. Ø., Hanauer, S. B., McColm, J., Bloomfield, R., & Sandborn, W. J. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa062897 · Cited by 1,043
Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial
Sandborn, W. J., Hanauer, S. B., Rutgeerts, P., Fedorak, R. N., Lukas, M., MacIntosh, D. G., Panaccione, R., Wolf, D., Kent, J. D., Bittle, B., et al. (2007) · Gut · doi:10.1136/gut.2006.106781 · Cited by 1,039
TNF neutralization in MS: Results of a randomized, placebo-controlled multicenter study
The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group (1999) · Neurology · doi:10.1212/wnl.53.3.457 · Cited by 1,017
Granulomatous Infectious Diseases Associated with Tumor Necrosis Factor Antagonists
Wallis, R. S., Broder, M. S., Wong, J. Y., Hanson, M. E., & Beenhouwer, D. O. (2004) · Clinical Infectious Diseases · doi:10.1086/383317 · Cited by 977
Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial
Sandborn, W. J., Hanauer, S. B., Katz, S., Safdi, M., Wolf, D. G., Baerg, R. D., Tremaine, W. J., Johnson, T., Diehl, N. N., & Zinsmeister, A. R. (2001) · Gastroenterology · doi:10.1053/gast.2001.28674 · Cited by 910
Mease, P. J., Gladman, D. D., Ritchlin, C. T., Ruderman, E. M., Steinfeld, S. D., Choy, E. H. S., Sharp, J. T., Ory, P. A., Perdok, R. J., & Weinberg, M. A. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21306 · Cited by 909
Etanercept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progression
Mease, P. J., Kivitz, A. J., Burch, F. X., Siegel, E. L., Cohen, S. B., Ory, P., Salonen, D., Rubenstein, J., Sharp, J. T., & Tsuji, W. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20335 · Cited by 882
van der Heijde, D., Kivitz, A., Schiff, M. H., Sieper, J., Dijkmans, B. A. C., Braun, J., Dougados, M., Reveille, J. D., Wong, R. L., Kupper, H., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21913 · Cited by 872
van der Heijde, D., Dijkmans, B., Geusens, P., Sieper, J., DeWoody, K., Williamson, P., & Braun, J. (2005) · Arthritis & Rheumatism · doi:10.1002/art.20852 · Cited by 860
Davis, J. C., Van Der Heijde, D., Braun, J., Dougados, M., Cush, J., Clegg, D. O., Kivitz, A., Fleischmann, R., Inman, R., Tsuji, W., et al. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11325 · Cited by 754
Dixon, W. G., Watson, K., Lunt, M., Hyrich, K. L., Silman, A. J., & Symmons, D. P. M. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21978 · Cited by 751
van Oosten, B. W., Barkhof, F., Truyen, L., Boringa, J. B., Bertelsmann, F. W., von Blomberg, B. M. E., Woody, J. N., Hartung, H.-P., & Polman, C. H. (1996) · Neurology · doi:10.1212/wnl.47.6.1531 · Cited by 733
Genovese, M. C., Bathon, J. M., Martin, R. W., Fleischmann, R. M., Tesser, J. R., Schiff, M. H., Keystone, E. C., Wasko, M. C., Moreland, L. W., Weaver, A. L., et al. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10308 · Cited by 733
Van den Brande, J. M. H., Braat, H., van den Brink, G. R., Versteeg, H. H., Bauer, C. A., Hoedemaeker, I., van Montfrans, C., Hommes, D. W., Peppelenbosch, M. P., & van Deventer, S. J. H. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00382-2 · Cited by 723
Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial
Antoni, C., Krueger, G. G., de Vlam, K., Birbara, C., Beutler, A., Guzzo, C., Zhou, B., Dooley, L. T., & Kavanaugh, A. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.032268 · Cited by 715
Infliximab Therapy in Patients with Chronic Sarcoidosis and Pulmonary Involvement
Baughman, R. P., Drent, M., Kavuru, M., Judson, M. A., Costabel, U., du Bois, R., Albera, C., Brutsche, M., Davis, G., Donohue, J. F., et al. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200603-402oc · Cited by 714
Treatment of Ankylosing Spondylitis by Inhibition of Tumor Necrosis Factor α
Gorman, J. D., Sack, K. E., & Davis, J. C. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012664 · Cited by 704
Infections in patients with rheumatoid arthritis treated with biologic agents
Listing, J., Strangfeld, A., Kary, S., Rau, R., von Hinueber, U., Stoyanova‐Scholz, M., Gromnica‐Ihle, E., Antoni, C., Herzer, P., Kekow, J., et al. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21386 · Cited by 681
Binding and Functional Comparisons of Two Types of Tumor Necrosis Factor Antagonists
Scallon, B., Cai, A., Solowski, N., Rosenberg, A., Song, X.-Y., Shealy, D., & Wagner, C. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.301.2.418 · Cited by 672
Brooklyn, T. N., Dunnill, M. G. S., Shetty, A., Bowden, J. J., Williams, J. D. L., Griffiths, C. E. M., Forbes, A., Greenwood, R., & Probert, C. S. (2006) · Gut · doi:10.1136/gut.2005.074815 · Cited by 646
Tubach, F., Salmon, D., Ravaud, P., Allanore, Y., Goupille, P., Bréban, M., Pallot‐Prades, B., Pouplin, S., Sacchi, A., Chichemanian, R. M., et al. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24632 · Cited by 632
Adalimumab with or without Methotrexate in Juvenile Rheumatoid Arthritis
Lovell, D. J., Ruperto, N., Goodman, S., Reiff, A., Jung, L., Jarosova, K., Nemcova, D., Mouy, R., Sandborg, C., Bohnsack, J., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706290 · Cited by 625
Hyrich, K. L., Watson, K. D., Silman, A. J., Symmons, D. P. M., & Register, T. B. B. (2006) · Rheumatology · doi:10.1093/rheumatology/kel149 · Cited by 623
van de Putte, L. B. A., Atkins, C., Malaise, M., Sany, J., Russell, A. S., van Riel, P. L. C. M., Settas, L., Bijlsma, J. W., Todesco, S., Dougados, M., et al. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.013052 · Cited by 617
Kavanaugh, A., McInnes, I., Mease, P., Krueger, G. G., Gladman, D., Gomez‐Reino, J., Papp, K., Zrubek, J., Mudivarthy, S., Mack, M., et al. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24403 · Cited by 602
Lichtenstein, G. R., Yan, S., Bala, M., Blank, M., & Sands, B. E. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.01.048 · Cited by 597
Inman, R. D., Davis, J. C., Heijde, D. V. D., Diekman, L., Sieper, J., Kim, S. I., Mack, M., Han, J., Visvanathan, S., Xu, Z., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23969 · Cited by 593
Lügering, A., Schmidt, M., Lügering, N., Pauels, H.-G., Domschke, W., & Kucharzik, T. (2001) · Gastroenterology · doi:10.1053/gast.2001.28702 · Cited by 588
Peyrin–Biroulet, L., Deltenre, P., de Suray, N., Branche, J., Sandborn, W. J., & Colombel, J. (2008) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2008.03.014 · Cited by 577
Keystone, E., Heijde, D. V. D., Mason, D., Landewé, R., Vollenhoven, R. V., Combe, B., Emery, P., Strand, V., Mease, P., Desai, C., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23964 · Cited by 576
Hoffman, G. S., Cid, M. C., Rendt-Zagar, K. E., Merkel, P. A., Weyand, C. M., Stone, J. H., Salvarani, C., Xu, W., Visvanathan, S., Rahman, M. U., et al. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-9-200705010-00004 · Cited by 563
Treatment recommendations for psoriatic arthritis
Ritchlin, C. T., Kavanaugh, A., Gladman, D. D., Mease, P. J., Helliwell, P., Boehncke, W.-H., de Vlam, K., Fiorentino, D., FitzGerald, O., Gottlieb, A. B., et al. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.094946 · Cited by 554
Keystone, E. C., Genovese, M. C., Klareskog, L., Hsia, E. C., Hall, S. T., Miranda, P. C., Pazdur, J., Bae, S.-C., Palmer, W., Zrubek, J., et al. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.099010 · Cited by 541
Jacobsson, L., Turesson, C., Gülfe, A., Kapetanovic, M. C., Petersson, I. F., Saxne, T., & Geborek, P. (2005) · PubMed · Cited by 533
Smolen, J. S., Kay, J., Doyle, M. K., Landewé, R., Matteson, E. L., Wollenhaupt, J., Gaylis, N., Murphy, F. T., Neal, J. S., Zhou, Y., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60506-7 · Cited by 526
Gordon, K. B., Langley, R. G., Leonardi, C., Toth, D., Menter, M. A., Kang, S., Heffernan, M., Miller, B., Hamlin, R., Lim, L., et al. (2006) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2006.05.027 · Cited by 510
TREATMENT OF ANKYLOSING SPONDYLITIS BY INHIBITION OF TUMOR NECROSIS FACTOR a
Orman, D., Enneth, K., Ack, E. S., Ohn, J., & Avis, C. D. (2002) · Cited by 470
Brandt, J., Khariouzov, A., Listing, J., Haibel, H., Sörensen, H., Grassnickel, L., Rudwaleit, M., Sieper, J., & Braun, J. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11017 · Cited by 458
The Safety and Efficacy of Infliximab in Moderate to Severe Chronic Obstructive Pulmonary Disease
Rennard, S. I., Fogarty, C., Kelsen, S., Long, W., Ramsdell, J., Allison, J., Mahler, D., Saadeh, C., Siler, T., Snell, P., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200607-995oc · Cited by 439
Mariette, X., Ravaud, P., Steinfeld, S., Baron, G., Goetz, J., Hachulla, E., Combe, B., Puéchal, X., Pennec, Y., Sauvezie, B., et al. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20146 · Cited by 437
Smolen, J. S., Van Der Heijde, D. M. F. M., St.Clair, E. W., Emery, P., Bathon, J. M., Keystone, E., Maini, R. N., Kalden, J. R., Schiff, M., Baker, D., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21678 · Cited by 434
Ruperto, N., Lovell, D. J., Cuttica, R., Wilkinson, N., Woo, P., Espada, G., Wouters, C., Silverman, E. D., Balogh, Z., Henrickson, M., et al. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22838 · Cited by 410
Etanercept Treatment for Children and Adolescents with Plaque Psoriasis
Paller, A. S., Siegfried, E. C., Langley, R. G., Gottlieb, A. B., Pariser, D., Landells, I., Hebert, A. A., Eichenfield, L. F., Patel, V., Creamer, K., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa066886 · Cited by 391
Etanercept for the Treatment of Stage II and III Progressive Pulmonary Sarcoidosis
Utz, J. P., Limper, A. H., Kalra, S., Specks, U., Scott, J. P., Vuk-Pavlovic, Z., & Schroeder, D. R. (2003) · Chest · doi:10.1378/chest.124.1.177 · Cited by 390
Quartier, P., Taupin, P., Bourdeaut, F., Lemelle, I., Pillet, P., Bost, M., Sibilia, J., Koné‐Paut, I., Gandon‐Laloum, S., LeBideau, M., et al. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10885 · Cited by 364
Probert, C. S. J., Hearing, S. D., Schreiber, S., Kühbacher, T., Ghosh, S., Arnott, I. D. R., & Forbes, A. (2003) · Gut · doi:10.1136/gut.52.7.998 · Cited by 355
Mitoma, H., Horiuchi, T., Tsukamoto, H., Tamimoto, Y., Kimoto, Y., Uchino, A., To, K., Harashima, S., Hatta, N., & Harada, M. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23447 · Cited by 346
Ohno, S., Nakamura, S., Hori, S., Shimakawa, M., Kawashima, H., Mochizuki, M., Sugita, S., Ueno, S., Yoshizaki, K., & 稲葉, 午. (2004) · PubMed · Cited by 343
Aringer, M., Graninger, W. B., Steiner, G., & Smolen, J. S. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20576 · Cited by 342
Fleischmann, R., Vencovsky, J., van Vollenhoven, R. F., Borenstein, D., Box, J., Coteur, G., Goel, N., Brezinschek, H.-P., Innes, A., & Strand, V (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.099291 · Cited by 338
The German etanercept registry for treatment of juvenile idiopathic arthritis
Horneff, G., Schmeling, H., Biedermann, T., Foeldvari, I., Ganser, G., Girschick, H. J., Hospach, T., Huppertz, H. I., Keitzer, R., Küster, R. M., et al. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.014886 · Cited by 318
Kaymakcalan, Z., Sakorafas, P., Bose, S., Scesney, S., Xiong, L., Hanzatian, D. K., Salfeld, J., & Sasso, E. H. (2009) · Clinical Immunology · doi:10.1016/j.clim.2009.01.002 · Cited by 317
Ko, J. M., Gottlieb, A. B., & Kerbleski, J. F. (2009) · Journal of Dermatological Treatment · doi:10.1080/09546630802441234 · Cited by 313
Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis
Calin, A., Dijkmans, B. A. C., Emery, P., Hakala, M., Kalden, J., Leirisalo-Repo, M., Mola, E. M., Salvarani, C., Sanmartí, R., Sany, J., et al. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.020875 · Cited by 311
TNFα blockade in human diseases: Mechanisms and future directions
Wong, M., Ziring, D., Korin, Y., Desai, S., Kim, S., Lin, J., Gjertson, D., Braun, J., Reed, E., & Singh, R. R. (2008) · Clinical Immunology · doi:10.1016/j.clim.2007.08.013 · Cited by 307
Psoriasis induced by anti–tumor necrosis factor therapy: A paradoxical adverse reaction
Sfikakis, P. P., Iliopoulos, A., Elezoglou, A., Kittas, C., & Stratigos, A. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21233 · Cited by 301
Self-citationAnti-TNF therapy in the management of Behcet's disease--review and basis for recommendations
Sfikakis, P. P., Markomichelakis, N., Alpsoy, E., Assaad-Khalil, S., Bodaghi, B., Gul, A., Ohno, S., Pipitone, N., Schirmer, M., Stanford, M., et al. (2007) · Rheumatology · doi:10.1093/rheumatology/kem034 · Cited by 301
Self-citationDonahue, K. E., Gartlehner, G., Jonas, D. E., Lux, L. J., Thieda, P., Jonas, B. L., Hansen, R. A., Morgan, L. C., & Lohr, K. N. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-2-200801150-00192 · Cited by 299
Kay, J., Matteson, E. L., Dasgupta, B., Nash, P., Durez, P., Hall, S., Hsia, E. C., Han, J., Wagner, C., Xu, Z., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23383 · Cited by 295
Etanercept Treatment in Children With New-Onset Type 1 Diabetes
Mastrandrea, L., Yu, J., Behrens, T., Buchlis, J., Albini, C., Fourtner, S., & Quattrin, T. (2009) · Diabetes Care · doi:10.2337/dc09-0054 · Cited by 280
Mitoma, H., Horiuchi, T., Hatta, N., Tsukamoto, H., Harashima, S.-I., Kikuchi, Y., Otsuka, J., Okamura, S., Fujita, S., & Harada, M. (2005) · Gastroenterology · doi:10.1053/j.gastro.2004.11.060 · Cited by 270
Braun, J., Brandt, J., Listing, J., Zink, A., Alten, R., Burmester, G., Golder, W., Gromnica‐Ihle, E., Kellner, H., Schneider, M., et al. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11104 · Cited by 264
Heiberg, M. S., Koldingsnes, W., Mikkelsen, K., Rødevand, E., Kaufmann, C., Mowinckel, P., & Kvien, T. K. (2008) · Arthritis Care & Research · doi:10.1002/art.23333 · Cited by 256
Lovell, D. J., Giannini, E. H., Reiff, A., Jones, O. Y., Schneider, R., Olson, J. C., Stein, L. D., Gedalia, A., Ilowite, N. T., Wallace, C. A., et al. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10710 · Cited by 250
TNFα blockade in human diseases: An overview of efficacy and safety
Lin, J., Ziring, D., Desai, S., Kim, S., Wong, M., Korin, Y., Braun, J., Reed, E., Gjertson, D., & Singh, R. R. (2008) · Clinical Immunology · doi:10.1016/j.clim.2007.08.012 · Cited by 244
Tumor necrosis factor α antagonist use and cancer in patients with rheumatoid arthritis
Setoguchi, S., Solomon, D. H., Weinblatt, M. E., Katz, J. N., Avorn, J., Glynn, R. J., Cook, E. F., Carney, G., & Schneeweiss, S. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22056 · Cited by 240
Zink, A., Strangfeld, A., Schneider, M., Herzer, P., Hierse, F., Stoyanova‐Scholz, M., Wassenberg, S., Kapelle, A., & Listing, J. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22193 · Cited by 239
Furst, D. E., Wallis, R., Broder, M., & Beenhouwer, D. O. (2006) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2006.02.001 · Cited by 233
Infliximab for Recurrent, Sight-Threatening Ocular Inflammation in Adamantiades–Behçet Disease
Sfikakis, P. P., Kaklamanis, P. H., Elezoglou, A., Katsilambros, N., Theodossiadis, P. G., Papaefthimiou, S., & Markomichelakis, N. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-140-5-200403020-00025 · Cited by 229
Self-citationAutoantibody formation in patients with rheumatoid arthritis treated with anti-TNFα
Eriksson, C., Engstrand, S., Sundqvist, K.-G., & Rantapää-Dahlqvist, S. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.024182 · Cited by 228
Wallis, R. S., Kyambadde, P., Johnson, J. L., Horter, L., Kittle, R., Pohle, M., Ducar, C., Millard, M., Mayanja-Kizza, H., Whalen, C., et al. (2004) · AIDS · doi:10.1097/00002030-200401230-00015 · Cited by 226
van Vollenhoven, R., Harju, A., Brannemark, S., & Klareskog, L. (2003) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.009589 · Cited by 221
Fautrel, B., Sibilia, J., Mariette, X., & Combe, B. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.024026 · Cited by 218
van der Kooij, S. M., Goekoop-Ruiterman, Y. P. M., de Vries-Bouwstra, J. K., Güler-Yüksel, M., Zwinderman, A. H., Kerstens, P. J. S. M., van der Lubbe, P. A. H. M., de Beus, W. M., Grillet, B. A. M., Ronday, H. K., et al. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.092254 · Cited by 213
Williams, E. L., Gadola, S., & Edwards, C. J. (2009) · Rheumatology · doi:10.1093/rheumatology/kep080 · Cited by 207
Salvarani, C., Macchioni, P., Manzini, C., Paolazzi, G., Trotta, A., Manganelli, P., Cimmino, M., Gerli, R., Catanoso, M. G., Boiardi, L., et al. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-9-200705010-00005 · Cited by 199
The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease
Cepeda, E. J., Williams, F. M., Ishimori, M. L., Weisman, M. H., & Reveille, J. D. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.081513 · Cited by 199
Vasculitides induced by TNFα antagonists: a study in 39 patients in France
Marcoux, B. S., & Bandt, M. D. (2006) · Joint Bone Spine · doi:10.1016/j.jbspin.2006.02.010 · Cited by 190
Kievit, W., Fransen, J., Oerlemans, A. J. M., Kuper, H. H., van der Laar, M. A. F. J., de Rooij, D. J. R. A. M., De Gendt, C. M. A., Ronday, K. H., Jansen, T. L., van Oijen, P. C. M., et al. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.072447 · Cited by 188
Kollias, G., & Kontoyiannis, D. (2002) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(02)00019-9 · Cited by 177
Finckh, A., Simard, J. F., Gabay, C., & Guerne, P.-A. (2006) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.045062 · Cited by 176
Korhonen, T., Karppinen, J., Paimela, L., Malmivaara, A., Lindgren, K.-A., Bowman, C., Hammond, A., Kirkham, B., Järvinen, S., Niinimäki, J., et al. (2006) · Spine · doi:10.1097/01.brs.0000245873.23876.1e · Cited by 174
Rossman, M. D., Newman, L. S., Baughman, R. P., Teirstein, A. S., Weinberger, S. E., Miller, W. T., & Sands, B. E. (2006) · PubMed · Cited by 166
Papadakis, K. A., Shaye, O. A., Vasiliauskas, E. A., Ippoliti, A., Dubinsky, M. C., Loane, J., Paavola, J., Lee, S. K., Price, J., Targan, S. R., et al. (2005) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2005.40647.x · Cited by 161
Infliximab for chronic cystoid macular edema associated with uveitis
Markomichelakis, N. N., THEODOSSIADIS, P. G., Pantelia, E., Papaefthimiou, S., THEODOSSIADIS, G. P., & Sfikakis, P. P. (2004) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2004.04.066 · Cited by 155
Self-citationCohen, S. P., Bogduk, N., Dragovich, A., Buckenmaier, C. C., Griffith, S. R., Kurihara, C., Raymond, J., Richter, P. J., Williams, N., & Yaksh, T. L. (2009) · Anesthesiology · doi:10.1097/aln.0b013e3181a05aa0 · Cited by 150
Esters, N., Vermeire, S., Joossens, S. B. A., Noman, M., Louis, E., Bélaïche, J., Vos, M. D., Gossum, A. M. V., Pescatore, P., Fiasse, R., et al. (2002) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2002.05689.x · Cited by 142
THEODOSSIADIS, P. G., Markomichelakis, N., & Sfikakis, P. P. (2007) · Retina · doi:10.1097/maj.0b013e3180318fbc · Cited by 136
Self-citationEtanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis.
Kimura, Y., Pinho, P., Walco, G. A., Higgins, G. C., Hummell, D. S., Szer, I. S., Henrickson, M., Watcher, S., & Reiff, A. O. (2005) · PubMed · Cited by 135
Feldman, S. R., Gordon, K. B., BALA, M. M., Evans, R., Li, S., Dooley, L. T., Guzzo, C. A., Patel, K. R., Menter, A., & Gottlieb, A. B. (2005) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2005.06510.x · Cited by 133
An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis
Denton, C. P., Engelhart, M., Tvede, N., Wilson, H., Khan, K., Shiwen, X., Carreira, P. E., Díaz‐González, F., Black, C. M., & van den Hoogen, F. H. J. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.096123 · Cited by 131
Guideline for anti-TNF-α therapy in psoriatic arthritis
Kyle, S., Chandler, D., Griffiths, C. E. M., Helliwell, P., Lewis, J., McInnes, I. B., Oliver, S., Symmons, D. P. M., & McHugh, N. J. (2005) · Rheumatology · doi:10.1093/rheumatology/keh514 · Cited by 129
Alexopoulou, L., Kranidioti, K., Xanthoulea, S., Denis, M. C., Kotanidou, A. N., Douni, E. K., Blackshear, P. J., Kontoyiannis, D. L., & Kollias, G. A. (2006) · European Journal of Immunology · doi:10.1002/eji.200635921 · Cited by 126
THEODOSSIADIS, P. G., Liarakos, V. S., Sfikakis, P. P., Vergados, I. A., & THEODOSSIADIS, G. P. (2009) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2008.12.004 · Cited by 120
Self-citationHueber, W., Tomooka, B. H., Batliwalla, F., Li, W., Monach, P. A., Tibshirani, R. J., van Vollenhoven, R., Lampa, J., Saito, K., Tanaka, Y., et al. (2009) · Arthritis Research & Therapy · doi:10.1186/ar2706 · Cited by 118
Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis
van der Bijl, A. E., Goekoop-Ruiterman, Y. P. M., Vries-Bouwstra, J. K. D., ten Wolde, S., Han, K. H., van Krugten, M. V., Allaart, C. F., Breedveld, F. C., & Dijkmans, B. A. C. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22718 · Cited by 117
Regression of neovascular age-related macular degeneration following infliximab therapy
Markomichelakis, N. N., THEODOSSIADIS, P. G., & Sfikakis, P. P. (2005) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2004.09.058 · Cited by 115
Self-citationKokkinos, A. D., Iliopoulos, A., Greka, P., et al. (2004) · Clinical Rheumatology · doi:10.1007/s10067-003-0775-5 · Cited by 96
Off-Label Dermatologic Uses of Anti-TNF-a Therapies
Alexis, A. F., & Strober, B. E. (2005) · Journal of Cutaneous Medicine and Surgery · doi:10.1007/s10227-005-0110-7 · Cited by 95
Safety of biologic therapies--an update.
Keystone, E. C. (2005) · PubMed · Cited by 92
Sfikakis, P. P., Markomichelakis, N. N., THEODOSSIADIS, G. P., Grigoropoulos, V. G., Katsilambros, N., & Theodossiadis, P. G. (2005) · Diabetes Care · doi:10.2337/diacare.28.2.445 · Cited by 92
Self-citationInhibitors of tumor necrosis factor (TNF) in sarcoidosis: who, what, and how to use them.
Baughman, R. P., Lower, E. E., & Drent, M. (2008) · PubMed · Cited by 91
Shen, C., Assche, G. V., Rutgeerts, P. J., & Ceuppens, J. L. (2005) · Inflammatory Bowel Diseases · doi:10.1097/01.mib.0000194185.69800.07 · Cited by 71
Baraliakos, X., Listing, J., Rudwaleit, M., Brandt, J., Alten, R., Burmester, G. R., Gromnica‐Ihle, E., Haibel, H., Schewe, S., Schneider, M., et al. (2007) · PubMed · Cited by 67
Tumor necrosis factor biology in experimental and clinical arthritis
Sfikakis, P. P., & Kollias, G. A. (2003) · Current Opinion in Rheumatology · doi:10.1097/00002281-200307000-00003 · Cited by 64
Self-citationBarnabe, C. C. M., & Hanley, D. A. (2008) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2008.04.004 · Cited by 61
Symmons, D. P. M., & Silman, A. J. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20312 · Cited by 60
Horneff, G., Ebert, A., Fitter, S., Minden, K., Foeldvari, I., Kümmerle-Deschner, J. B., Thon, A., Girschick, H. J., Weller, F., & Huppertz, H. ‐. (2009) · Lara D. Veeken · doi:10.1093/rheumatology/kep122 · Cited by 56
Feagan, B. G., Coteur, G., Tan, S., Keininger, D. L., & Schreiber, S. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.199 · Cited by 47
Nannini, C., Cantini, F., Niccoli, L., et al. (2009) · Arthritis Care & Research · doi:10.1002/art.24506 · Cited by 42
Infliximab treatment-induced formation of autoantibodies is common in Behçet's disease.
Elezoglou, A. V., Kafasi, N., Kaklamanis, P. G., THEODOSSIADIS, P. G., Kapsimali, V., Choremi, E., Vaiopoulos, G., & Sfikakis, P. P. (2007) · PubMed · Cited by 30
Self-citationInfliximab in dermatological treatment: beyond psoriasis
Rigopoulos, D., Korfitis, C., Gregoriou, S., & Katsambas, A. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.1.123 · Cited by 17
Tzelepis, G. E., Kalliakosta, G., Tzioufas, A. G., Sfikakis, P. P., Mandros, C., Boki, K., Roussos, C., & Moutsopoulos, H. M. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.092650 · Cited by 11
Self-citation
Cited by
Austin, P. J., & Moalem-Taylor, G. (2010) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2010.08.013 · Cited by 607
Thompson, J. A., Schneider, B. J., Brahmer, J., Andrews, S., Armand, P., Bhatia, S., Budde, L. E., Costa, L., Davies, M., Dunnington, D., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0013 · Cited by 570
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020
Thompson, J. A., Schneider, B. J., Brahmer, J., Andrews, S., Armand, P., Bhatia, S., Budde, L. E., Costa, L., Davies, M., Dunnington, D., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0012 · Cited by 485
Importance of glial activation in neuropathic pain
Mika, J., Zychowska, M., Popiolek-Barczyk, K., Rojewska, E., & Przewlocka, B. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.01.072 · Cited by 460
Mehta, A. K., Gracias, D. T., & Croft, M. (2018) · Cytokine · doi:10.1016/j.cyto.2016.08.003 · Cited by 404
Metadata
- Authors
- Sfikakis, P. P.
- Venue
- Current Directions in Autoimmunity
- Publisher
- KARGER
- Published
- 2010
- Volume
- 11
- Pages
- 180-210
- ISSN
- 1422-2132 (ISSN-L)
- OpenAlex
- W1601972531
- Cited by
- 275
- References
- 134
- FWCI
- 215.46
- Type
- book chapter
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.